Full-Time

Senior Solutions Architect

Posted on 8/15/2025

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Blackpool, UK

Hybrid

Hybrid working arrangement.

Category
Sales & Solution Engineering (1)
Required Skills
Microsoft Azure
Salesforce
Requirements
  • Proven experience working in IT across a range of roles
  • Proven experience working as a Solution Architect
  • Experience of working in a large enterprise with matrix management
  • Degree in a relevant subject or evidence of significant experience in Architecture teams
  • Experience working within a large international matrix managed organisation
  • Knowledge of SAP S4, Azure, Manhattan, Salesforce and other leading Software providers
  • Experience in the pharmaceutical, wholesale or logistics industry
  • Multinational / Global organisation
  • Use of Architecture tools and frameworks
  • Demonstrates a proactive, can-do attitude and takes full accountability and ownership. Adaptable to a fast-paced environment, adept at managing competing priorities.
  • Possesses exceptional analytical and problem-solving capabilities, adept at multitasking effectively.
  • Excels under pressure, thrives in ambiguous situations while maintaining a steadfast focus on achieving results.
  • Enthusiastically committed to delivering a consistently high standard of work.
  • Exhibits strong written and verbal communication skills.
  • Cultivates robust relationship-building and stakeholder management abilities.
  • Demonstrates an ability for influencing effectively.
  • Collaborates effectively within teams and values teamwork.
  • Offers creative insights and contributes effectively to a team while being self-motivated and capable of taking initiative.
  • Balances meticulous attention to detail with the commitment to see projects through to completion.
  • Works seamlessly as part of an international team.
Responsibilities
  • Develops high-level solution designs for programs or projects, leveraging expertise from domain specialists and third-party solution providers to ensure alignment with business needs, suitability, and supportability.
  • Adopts a comprehensive approach to solution design, considering broader factors such as business strategic goals, future architectural vision, the existing IT landscape, and the IT portfolio plan.
  • Provides high-level cost estimates to facilitate comparison of options and design recommendations.
  • Seeks design approval from the Architecture Governance Forum.
  • Cultivates strong relationships with business stakeholders, gaining insight into their objectives and serving as a trusted advisor for technology decisions, effectively communicating architectural considerations.
  • Collaborates with third-party solution providers to explore opportunities and assess their compatibility with our requirements.
  • Engages with business stakeholders to evaluate the suitability of products and services based on functional and non-functional requirements, technology standards, and architectural principles.
  • Demonstrates commercial awareness, working with technology vendors to comprehend their commercial models and decipher complex licensing agreements.
  • Effectively communicates design decisions and recommendations, along with their rationale, to both business and IT stakeholders.
  • Ensures the management and maintenance of the application portfolio for Alliance Healthcare UK, integrating it into the broader context.
  • Ensures that application, data, infrastructure requirements, as well as system interdependencies and integration needs, are identified, documented, and incorporated into the solution design.
  • Operates within the guidelines of the Enterprise Architecture Framework and maintains the information within the Enterprise Architecture repository.
  • Identifies potential project prerequisites or interdependencies, understands their implications, and communicates them to affected projects, aiming to minimize rigid dependencies between projects.
  • Offers design governance during the project delivery phase to uphold the integrity of the solution design and facilitate the thorough evaluation of changes.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
  • EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
  • FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.

What critics are saying

  • Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
  • McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
  • Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.

What makes Cencora unique

  • Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
  • Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
  • Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE